Noah Labs welcomed as first startup at Herz-Hirn-Allianz initiated by Novartis.
.webp)
With the signing of the joint declaration, Noah Labs was accepted as the very first startup among globally leading pharma and medtech firms to join Herz-Hirn-Allianz. Led by Novartis, the initiative fights to reduce cardiovascular events by 30 percent by 2030. The interdisciplinary group is made up of global pharmaceutical and medical technology companies such as Abbott, Novartis and Siemens Healthineers. It also includes patient representatives, health insurers and politicians.
““Led by Novartis, the initiative fights to reduce cardiovascular events by 30 percent by 2030.”
About Herz-Hirn-Allianz
With scientific support from the WifOR Institute and the Institute for Health Economics (IfG), the Herz-Hirn-Allianz aims to reduce cardiovascular events by 30 percent by 2030. The alliance of experts initiates concrete measures to raise general awareness, promote prevention, optimize patient pathways and advance research.Fields of action of Herz-Hirn-AllianzRaise awareness: Raise health literacy and awareness among the population with high-reach campaigns. Promote prevention: Reduce risk factors through targeted primary, secondary and tertiary prevention and thus prevent diseases and secondary diseases in a patient-oriented manner. Optimize patient pathways: Using newly conceived and low-threshold early detection measures, diagnoses can be made promptly and structured treatment paths implemented.Advance research: Promote innovative therapies with interdisciplinary research to better combat cardiovascular diseases in the future.
About Noah Labs
At Noah Labs, our vision is to enable people to live longer and happier lives despite their cardiovascular condition. We utilize advanced technology to deliver personalized and predictive virtual care at home. Backed by artificial intelligence and machine learning, our solution reduces both mortality and morbidity while enabling cost savings for health systems. Noah Labs develops an AI-powered health analytics platform that combines smart biosensors, machine learning software, and a mobile app for patients. Through digital biomarkers, the system predicts the onset of medical deterioration in advance of a cardiac event, alerts health care providers accordingly, and guides intervention with drug-based therapy optimization.
With scientific support from the WifOR Institute and the Institute for Health Economics (IfG), the Herz-Hirn-Allianz aims to reduce cardiovascular events by 30 percent by 2030. The alliance of experts initiates concrete measures to raise general awareness, promote prevention, optimize patient pathways and advance research.Fields of action of Herz-Hirn-AllianzRaise awareness.
Raise health literacy and awareness among the population with high-reach campaigns. Promote prevention: Reduce risk factors through targeted primary, secondary and tertiary prevention and thus prevent diseases and secondary diseases in a patient-oriented manner.
Optimize patient pathways: Using newly conceived and low-threshold early detection measures, diagnoses can be made promptly and structured treatment paths implemented.Advance research: Promote innovative therapies with interdisciplinary research to better combat cardiovascular diseases in the future.
At Noah Labs, our AI-powered approach to cardiovascular care and research is dedicated to helping people with cardiovascular disease live longer, healthier lives. The Noah Labs Ark cardiovascular software platform enables cardiologists to efficiently monitor patients with heart failure through telemedicine, utilizing external measurement devices such as smartwatches, blood pressure cuffs, and scales. These devices wirelessly transmit health data to the Noah Labs Ark, where it is continuously analyzed, allowing doctors to detect changes early and respond immediately.
In addition to this, we are developing innovative voice-based machine learning software designed for the early detection of decompensated heart failure - the leading cause of hospitalization. This cutting-edge technology analyzes changes in vocal tone caused by pulmonary edema and fluid accumulation, detecting deterioration up to 14 days before current standard methods. By doing so, it helps avoid costly hospitalizations. Our patented solution is undergoing testing at prestigious institutions including the Mayo Clinic in the USA, Charité in Berlin, and university hospitals in Maastricht and Barcelona.
Founded in 2021 by physician Dr. Leonhard Riehle, machine learning engineer Marcus Hott, and serial entrepreneur Oliver Piepenstock, we are an ISO 13485 certified manufacturer of software-based medical devices, currently employing 20 dedicated professionals.